SkyePharma PLC announced that its third phase III efficacy study evaluating Flutiform for the treatment of mild to moderate asthma in adolescent and adult patients has met its primary endpoints. This is the third of several clinical efficacy studies being carried out in preparation for regulatory filing and completes the original core clinical trial programme.
The details can be read here.
No comments:
Post a Comment